Investors & Media

We are progressing our lead program in AMN (SBT101), in addition to further developing a pipeline of gene therapy candidates designed to be delivered intrathecally. Our forward momentum is currently powered by a $56M Series B investment from our long-term, committed investment partners.

Press Releases & Announcements

Follow our progress and read our most recent announcements:

    Investor
    Inquiries

    Jan Case
    investors@swanbiotx.com

     

    Media
    Queries

    Lara Furst
    703-946-0183
    media@swanbiotx.com